

Ireland-Dublin: Medicinal products for the blood, blood-forming organs and the cardiovascular system**OJ S 115/2023 16/06/2023****Contract notice****Supplies****Legal Basis:**

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: Irish Blood Transfusion Service

Postal address: National Blood Centre , James's Street

Town: Dublin

NUTS code: IE Éire / Ireland

Postal code: D08 NH5R

Country: Ireland

Contact person: Brian Boland

E-mail: brian.boland@ibts.ie**Internet address(es):**Main address: <https://www.etenders.gov.ie>Address of the buyer profile: <https://www.etenders.gov.ie>**I.2. Information about joint procurement**

The contract is awarded by a central purchasing body

I.3. Communication

Access to the procurement documents is restricted. Further information can be obtained at:

<https://www.etenders.gov.ie>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://www.etenders.gov.ie>**I.4. Type of the contracting authority**

Body governed by public law

I.5. Main activity

Health

Section II: Object

II.1. Scope of the procurement**II.1.1. Title**

Fibrinogen concentrate used for congenital afibrinogenaemia and dysfibrinogenaemia

II.1.2. Main CPV code

33620000 Medicinal products for the blood, blood-forming organs and the cardiovascular system

II.1.3. Type of contract

Supplies

II.1.4. Short description

Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

II.1.5. Estimated total value

II.1.6. Information about lots

This contract is divided into lots: no

II.2. Description

II.2.2. Additional CPV code(s)

33621000 Medicinal products for the blood and blood-forming organs, 33622000 Medicinal products for the cardiovascular system

II.2.3. Place of performance

NUTS code: IE Éire / Ireland

II.2.4. Description of the procurement

Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 36

This contract is subject to renewal: yes

Description of renewals:

As per RFT

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section III: Legal, economic, financial and technical information

III.1. Conditions for participation

III.1.2. Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3. Technical and professional ability

Selection criteria as stated in the procurement documents

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

IV.1.8. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: no

IV.2. Administrative information

IV.2.2. Time limit for receipt of tenders or requests to participate

Date: 28/07/2023 Local time: 12:00

IV.2.3. Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4. Languages in which tenders or requests to participate may be submitted

English

IV.2.6. Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7. Conditions for opening of tenders

Date: 28/07/2023 Local time: 12:30

Section VI: Complementary information

VI.1. Information about recurrence

This is a recurrent procurement: yes

Estimated timing for further notices to be published:

As per RFT

VI.2. Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3. Additional information**VI.4. Procedures for review****VI.4.1. Review body**

Official name: Irish Blood Transfusion Services

Postal address: National Blood Centre , James's Street

Town: Dublin

Postal code: D08 NH5R

Country: Ireland

E-mail: brian.boland@ibts.ie

VI.5. Date of dispatch of this notice

13/06/2023